<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0702244867
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Cenoril
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PERINDOPRIL ARGININE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        36.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Alrai Pharmaceutical industry Co. (L.L.C)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Alrai Pharmaceutical industry Co. (L.L.C)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Alrai Pharmaceutical industry Co. (L.L.C)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09AA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cenoril is an angiotensin converting enzyme (ACE) inhibitor. These work by widening the blood vessels, which makes it easier for your heart to pump blood through them.</p><p>Cenoril is used:</p><p>&bull; to treat high blood pressure (hypertension),</p><p>&bull; to treat heart failure (a condition where the heart is unable to pump enough blood to meet the body&rsquo;s needs),</p><p>&bull; to reduce the risk of cardiac events, such as heart attack, in patients with stable coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) and who have already had a heart attack and/or an operation to improve the blood supply to the heart by widening the vessels that supply it.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Cenoril </strong></p><p>&bull; If you are allergic to perindopril, or any of the other ingredients of this medicine (listed in Section 6), or to any other ACE inhibitor,</p><p>&bull; If you have experienced symptoms such as wheezing, swelling of the face, tongue or throat, intense itching or severe skin rashes with previous ACE inhibitor treatment or if you or a member of your family have had these symptoms in any other circumstances (a condition called angioedema),</p><p>&bull; If you are more than 3 months pregnant. (It is also better to avoid Cenoril in early pregnancy &ndash; see pregnancy section),</p><p>&bull; If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p>&bull; If you are having dialysis or any other type of blood filtration. Depending on the machine that is used, Cenoril may not be suitable for you,</p><p>&bull; If you have kidney problems where the blood supply to your kidneys is reduced (renal artery stenosis),</p><p>&bull; If you have taken or are currently taking sacubitril/valsartan, a medicine for heart failure, as the risk of angioedema (rapid swelling under the skin in an area such as the throat) is increased ( see&rdquo;<strong> </strong>Warnings and precautions&rdquo; and &ldquo;Other medicines and Cenoril &rdquo;).</p><p><strong>Warnings and precautions</strong></p><p>If any of the following apply to you please talk to your doctor or pharmacist or nurse before taking Cenoril if you:</p><p>&bull; have aortic stenosis (narrowing of the main blood vessel leading from the heart) or hypertrophic cardiomyopathy (heart muscle disease) or renal artery stenosis (narrowing of the artery supplying the kidney with blood),</p><p>&bull; have any other heart problems,</p><p>&bull; have liver problems,</p><p>&bull; have kidney problems or if you are receiving dialysis,</p><p>&bull; have abnormal increase level of a hormone called aldosterone in your blood (primary aldosteronism),</p><p>&bull; suffer from a collagen vascular disease (disease of the connective tissue) such as systemic lupus erythematosus or scleroderma,</p><p>&bull; have diabetes,</p><p>&bull; are on a salt restricted diet or use salt substitutes which contain potassium,</p><p>&bull; are to undergo anaesthesia and/or major surgery,</p><p>&bull; are to undergo LDL apheresis (which is removal of cholesterol from your blood by a machine),</p><p>&bull; are going to have desensitisation treatment to reduce the effects of an allergy to bee or wasp stings,</p><p>&bull; have recently suffered from diarrhoea or vomiting or are dehydrated,</p><p>&bull; have been told by your doctor that you have an intolerance to some sugars.</p><p>&bull; are taking any of the following medicines used to treat high blood pressure:</p><p>- An &ldquo; angiontensin II receptor blocker&rdquo; (ARBs) (also known as sartans- for example valsartan, telmisartan, irbesartan), in particular if you have diabetes-related kidney problems,</p><p>- Aliskiren,</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>See also information under the heading &ldquo;Do not take Cenoril &rdquo;.</p><p>&bull; are of black origin since you may have a higher risk of angioedema and this medicine may be less effective in lowering your blood pressure than in non-black patients,</p><p>&bull; are taking any of the following medicines, the risk of angioedema is increased:</p><p>- Racecadotril (used to treat diarrhoea),</p><p>- Sirolimus, everolimus, temsirolimus and other drugs belonging to the class of so-called mTor inhibitors (used to avoid rejection of transplanted organs and for cancer),</p><p>- Sacubitril (available as fixed-dose combination with valsartan), used to treat long-term heart failure,</p><p>- Linagliptin, saxagliptin, sitagliptin, vildagliptin and other drugs belonging to the class of the also called gliptins (used to treat diabetes).</p><p><u>Angioedema </u></p><p>Angioedema (a severe allergic reaction with swelling of the face, lips, tongue or throat with difficulty in swallowing or breathing) has been reported in patients treated with ACE inhibitors, including Cenoril . This may occur at any time during treatment. If you develop such symptoms, you should stop taking Cenoril and see a doctor immediately. See also section 4.</p><p>You must tell your doctor if you think are (<u>or might become</u>) pregnant. Cenoril is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p><strong>Children and adolescents</strong></p><p>The use of perindopril in children and adolescents up to the age of 18 years is not recommended.</p><p><strong>Other medicines and Cenoril </strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taking or may take any other medicines.</p><p>Treatment with Cenoril can be affected by other medicines. Your doctor may need to change your dose and/or to take other precautions. These include:</p><p>&bull; Other medicines for high blood pressure, including angiotensin II receptor blockers (ARB), aliskiren (see also information under the headings &ldquo;Do not take Cenoril &rdquo; and &ldquo;Warnings and precautions&rdquo;) or diuretics (medicines which increase the amount of urine produced by the kidneys),</p><p>&bull; Potassium-sparing drugs (e.g. triamterene, amiloride), potassium supplements or potassium-containing salt substitutes, other drugs which can increase potassium in your body (such as heparin, a medicine used to thin blood to prevent clots; trimethoprim and co-trimoxazole also known as trimethoprim/sulfamethoxazole for infections caused by bacteria),</p><p>&bull; Potassium-sparing drugs used in the treatment of heart failure: eplerenone and spironolactone at doses between 12.5 mg to 50 mg per day,</p><p>&bull; lithium for mania or depression,</p><p>&bull; non-steroidal anti-inflammatory drugs (e.g. ibuprofen) for pain relief or high dose acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever, as well as to prevent blood clotting,</p><p>&bull; medicines to treat diabetes (such as insulin or metformin),</p><p>&bull; baclofen (used to treat muscle stiffness in diseases such as multiple sclerosis),</p><p>&bull; medicines to treat mental disorders such as depression, anxiety, schizophrenia etc (e.g., tricyclic antidepressants, antipsychotics),</p><p>&bull; Immunosuppressants (medicines which reduce the defence mechanism of the body) used for the treatment of auto-immune disorders or following transplant surgery (e.g. ciclosporin, tacrolimus),</p><p>&bull; Trimethoprim (for the treatment of infections),</p><p>&bull; Estramustine (used in cancer therapy),</p><p>&bull; Medicines, which are most often used to treat diarrhoea (racecadotril) or avoid rejection of transplanted organs (sirolimus, everlimus, temsirolimus and other drugs belonging to the class of so-called mTor inhibitors). See section &ldquo;Warnings and precautions&rdquo;,</p><p>&bull; Sacubitril/valsartan (used to treat long-term heart failure). See section &ldquo;Do not take Cenoril &rdquo; and &ldquo;Warnings and precautions&rdquo;,</p><p>&bull; allopurinol (for the treatment of gout),</p><p>&bull; procainamide (for the treatment of an irregular heart beat),</p><p>&bull; vasodilators including nitrates (products that make the blood vessels become wider),</p><p>&bull; medicines used for the treatment of low blood pressure, shock or asthma (e.g., ephedrine, noradrenaline or adrenaline),</p><p>&bull; gold salts, especially with intravenous administration (used to treat symptoms of rheumatoid arthritis).</p><p><strong>Cenoril with food and drink </strong></p><p>It is preferable to take Cenoril before a meal.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Pregnancy</strong></p><p>You must tell your doctor if you think you are <u>(or might become)</u> pregnant. Your doctor will normally advise you to stop taking Cenoril before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Cenoril.</p><p>Cenoril is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p><strong>Breast-feeding</strong></p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. Cenoril is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p><strong>Driving and using machines</strong></p><p>Cenoril usually does not affect alertness but dizziness or weakness due to low blood pressure may occur in certain patients. If you are affected in this way, your ability to drive or to operate machinery may be impaired.</p><p><strong>Cenoril contains lactose </strong></p><p>Cenoril contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you.</p><p>Check with your doctor or pharmacist if you are not sure.</p><p>Swallow your tablet with a glass of water, preferably at the same time each day, in the morning, before a meal. Your doctor will decide on the correct dose for you.</p><p><strong>The recommended dosages are as follows: </strong></p><p><strong><em>High blood pressure</em></strong><strong>:</strong> the usual starting and maintenance dose is 5 mg once daily. After one month, this can be increased to 10 mg once a day if required. 10 mg a day is the maximum recommended dose for high blood pressure. If you are 65 or older, the usual starting dose is 2.5 mg once a day. After a month this can be increased to 5 mg once a day and then if necessary to 10 mg once daily.</p><p><strong><em>Heart failure</em></strong><strong>:</strong> the usual starting dose is 2.5 mg once daily. After two weeks, this can be increased to 5 mg once a day, which is the maximum recommended dose for heart failure.</p><p><strong><em>Stable coronary artery disease</em></strong><strong>:</strong> the usual starting dose is 5 mg once daily. After two weeks, this can be increased to 10 mg once daily, which is the maximum recommended dose in this indication.</p><p>If you are 65 or older, the usual starting dose is 2.5 mg once a day. After a week this can be increased to 5 mg once a day and after a further week to 10 mg once daily.</p><p><strong>Use in children and adolescents</strong></p><p>Use in children and adolescents is not recommended.</p><p><strong>If you take more Cenoril than you should</strong></p><p>If you take too many tablets, contact your nearest accident and emergence department or tell your doctor immediately. The most likely effect in case of overdose is low blood pressure which can make you feel dizzy of faint. If this happens, lying down with the leg raised can help.</p><p><strong>If you forget to take Cenoril </strong></p><p>It is important to take your medicine every day as regular treatment works better. However, if you forget to take a dose of Cenoril , take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Cenoril </strong></p><p>As the treatment with Cenoril is usually life-long, you should discuss with your doctor before stopping this medicinal product.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Stop taking the medicinal product and see a doctor immediately, if you experience any of the following side effects </strong>that can be serious:</p><p>&bull; swelling of the face, lips, mouth, tongue or throat, difficulty in breathing (angioedema) (see section 2 &ldquo;Warnings and precautions&rdquo;) (Uncommon-may affect up to 1 in 100 people),</p><p>&bull; severe dizziness or fainting due to low blood pressure (Common-may affect up to 1 in 10 people),</p><p>&bull; unusual fast or irregular heartbeat, chest pain (angina) or heart attack (Very rare- may affect up to 1 in 10,000 people),</p><p>&bull; weakness of arms or legs, or problems speaking which could be sign of a possible stroke (Very rare- may affect up to 1 in 10,000 people),</p><p>&bull; sudden wheeziness, chest pain, shortness of breath, or difficulty in breathing (bronchospasm) (Uncommon-may affect up to 1 in 100 people),</p><p>&bull; inflamed pancreas which may cause severe abdominal and back pain accompanied with feeling very unwell (Very rare- may affect up to 1 in 10,000 people),</p><p>&bull; yellowing of the skin or eyes (jaundice) which could be sign of hepatitis (Very rare- may affect up to 1 in 10,000 people),</p><p>&bull; skin rash which often starts with red itchy patches on your face, arms or legs (erythema multiforme) (Very rare- may affect up to 1 in 10,000 people).</p><p><strong>Tell your doctor if you notice any of the following side effects:</strong></p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><p>&bull; headach,</p><p>&bull; dizziness,</p><p>&bull; vertigo,</p><p>&bull; pins and needles,</p><p>&bull; vision disturbances,</p><p>&bull; tinnitus (sensation of noises in the ears),</p><p>&bull; cough,</p><p>&bull; shortness of breath (dyspnoea),</p><p>&bull; gastrointestinal disorders (nausea, vomiting, abdominal pain, teste disturbances, dyspepsia of difficulty of digestion, diarrhoea, constipation),</p><p>&bull; allergic reactions (such as skin rashes, itching),</p><p>&bull; muscle cramps,</p><p>&bull; feeling of weakness.</p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><p>&bull; depression,</p><p>&bull; mood swings,</p><p>&bull; sleep disturbances,</p><p>&bull; dry mouth,</p><p>&bull; intense itching or severe skin rashes,</p><p>&bull; formation of blister clusters over the skin,</p><p>&bull; kidney problems,</p><p>&bull; impotence,</p><p>&bull; sweating,</p><p>&bull; excess of eosinophils (a type of white blood cells),</p><p>&bull; somnolence,</p><p>&bull; fainting,</p><p>&bull; palpitations,</p><p>&bull; tachycardia,</p><p>&bull; vasculitis (inflammation of blood vessels),</p><p>&bull; photosensitivity reaction (increased sensitivity if the skin to sun),</p><p>&bull; arthralgia (joint pain),</p><p>&bull; myalgia (muscle pain),</p><p>&bull; chest pain,</p><p>&bull; malaise.</p><p>&bull; oedema peripheral.</p><p>&bull; fever,</p><p>&bull; fall,</p><p>&bull; change in laboratory parameters: high blood level of potassium reversible on discontinuation, low level of sodium, hypoglycaemia (very low blood sugar level) in case of diabetic patients, increased blood urea and increased blood creatinine.</p><p><strong>Rare (may affect up to 1 in 1000 people):</strong></p><p>&bull; acute renal failure,</p><p>&bull; dark urine, feeling sick (nausea) or being sick (vomiting), muscle cramps, confusion and seizures. These may be symptoms of a condition call SIADH (inappropriate antidiuretic hormone secretuin),</p><p>&bull; decreased or absent urine output,</p><p>&bull; flushing,</p><p>&bull; psoriasis worsening,</p><p>&bull; changes in laboratory parameters: Increased level of liver enzymes, high level of serum bilirubin.</p><p><strong>Very rare (may affect up to 1 in 10,000 people):</strong></p><p>&bull; confusion,</p><p>&bull; eosinophilic pneumonia (a rare type of pneumonia),</p><p>&bull; rhinitis (blocked up or runny nose),</p><p>&bull; changes in blood values such as a lower number of white and red blood cells, lower haemoglobin, lower number of blood platelets.</p><p>If you have these symptoms contact your doctor as soon as possible.</p><p>Frequency not known (cannot be estimated from available data):</p><p>&bull; Discoloration, numbness and pain in fingers or toes (Raynaud&rsquo;s phenomenon).</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any possible side effects not listed in this leaflet, please tell your doctor or pharmacist. You can also report side effects directly (see section 6). By reporting side-effects you can help provide more information on the safety of this medicine.</p><p><strong>To report any side effect(s):</strong></p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; npc.drug@sfda.gov.sa</p><p>Website: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children.</p><p>&bull; Do not use them after the expiry date that is printed on the pack after &ldquo;EXP:&rdquo;. The expiry date refers to the last day of that month.</p><p>&bull; Store below 30 &deg;C.</p><p>&bull; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Cenoril contains</strong></p><p><strong>The active substance is</strong> perindopril arginine.</p><p><u>Each Cenoril 5 mg film-coated tablet</u> contains 5 mg perindopril arginine</p><p><u>Each Cenoril 10 mg film-coated tablet</u> contains 10 mg perindopril arginine</p><p><strong>The other ingredients in the tablet are:</strong> spray dried lactose, sodium starch glycolate, maltodextrin 19, colloidal silicon dioxide, magnesium stearate, Opadry blue.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cenoril 5 mg film-coated tablets are Blue, oblong shaped film coated tablets embossed with “F7” on one side and break line on the other side. The tablet can be divided into equal halves.
Cenoril 10 mg film-coated tablets are Blue, Round shaped, film coated tablets, embossed with ′F6` on one side and plain on the other side.
Cenoril film-coated tablets are available in blister packs containing 10 tablets and each box Contains three blisters (30 tablets).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Alrai Pharmaceutical Industries Co. (L.L.C.)</p><p>Al Wadi, Building No. 2684, Additional No. 6236</p><p>Unit No. 1, Jeddah 22518 Almu&rsquo;tasem Bellah Al Fatemy Street</p><p>P.O.Box: 9224 Jeddah - 21413 Kingdom of Saudi Arabia</p><p><u>Tel</u>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +966 12 2888949</p><p><u>E-mail:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; info@alraipharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 10/2023, Revision 0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">سينوريل هو عبارة عن مثبط للإنزيم المحول للأنجيوتنسين (ACE inhibitor)، وهو يقوم بتوسيع الأوعية الدموية مسهلاً بذلك عمل القلب بضخ الدم عبرها.</p><p dir="RTL">يستخدم سينوريل:</p><p dir="RTL">&nbsp;&bull;لعلاج ارتفاع ضغط الدم،</p><p dir="RTL">&nbsp;&bull;لعلاج فشل القلب (حالة يكون فيها القلب غير قادر على ضخ ما يكفي من الدم لتلبية احتياجات الجسم) ،</p><p dir="RTL">&nbsp;&bull;للحد من مخاطر الأحداث القلبية، مثل السكتة القلبية، في المرضى الذين يعانون من مرض الشريان التاجي الثابت (حالة تقل فيها إمداد القلب بالدم أو انسداده) والذين أصيبوا بالفعل بنوبة قلبية و / أو قاموا بعملية تحسين تدفق الدم إلى القلب عن طريق توسيع الأوعية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول سينوريل:</strong></p><p dir="RTL">&bull; إذا كانت لديك حساسية من البيريندوبريل، أو من أي من مكونات سينوريل الأخرى (المدرجة في القسم 6)، أو أي من الأدوية الأخرى التابعة لمثبطات الإنزيم المحول للأنجيوتنسين.</p><p dir="RTL">&nbsp;&bull;إذا كنت قد عانيت من أعراض مثل الصفير، أو تورم الوجه أو اللسان أو الحلق، أو الحكة الشديدة أو الطفح الجلدي الشديد عند العلاج بمثبطات الإنزيم المحول للأنجيوتنسين سابقاً أو إذا عانيت أنت أو أحد أفراد عائلتك من هذه الأعراض في أي ظروف أخرى (حالة تسمى الوذمة الوعائية) ،</p><p dir="RTL">&nbsp;&bull;إذا كنتِ حاملاً منذ أكثر من ثلاثة أشهر. (من الأفضل أيضًا تجنب سينوريل في بداية الحمل (أنظري &quot;الحمل و الرضاعة&quot;)،</p><p dir="RTL">&nbsp;&bull;إذا كنت تعاني من مرض السكري أو ضعف وظائف الكلى وتتلقى علاجًا خافضًا لضغط الدم يحتوي على أليسكيرين.</p><p dir="RTL">&nbsp;&bull;إذا كنت تخضع لغسيل الكلى أو أي نوع آخر من ترشيح الدم. اعتمادًا على الجهاز المستخدم، قد لا يكون سينوريل مناسبًا لك،</p><p dir="RTL">&nbsp;&bull;إذا كنت تعاني من مشاكل في الكلى حيث يقل تدفق الدم إلى كليتيك (تضيق الشريان الكلوي) ،</p><p dir="RTL">&nbsp;&bull;إذا كنت قد تناولت في السابق دواء ساكوبتريل / فالسارتان أو تتناوله حاليًا، وهو دواء لعلاج قصور القلب، حيث يزداد خطر الإصابة بالوذمة الوعائية (التورم السريع تحت الجلد في منطقة مثل الحلق) (انظر &quot;المحاذير والاحتياطات&quot; و &quot;سينوريل والأدوية الأخرى&quot;).</p><p dir="RTL"><strong>المحاذير والاحتياطات</strong></p><p dir="RTL">إذا انطبق عليك أي مما يلي، يرجى التحدث إلى طبيبك أو الصيدلي أو الممرض قبل تناول سينوريل إذا كنت:</p><p dir="RTL">&nbsp;&bull; تعاني من تضيّق أبهري (أي تضيّق في الشريان الرئيسي الذي يخرج من القلب) ، أو تضخم عضلة القلب (مرض في عضلة القلب) أو تضيق الشريان الكلوي (تضيق الشريان الذي يغذي الكلى بالدم) ،</p><p dir="RTL">&bull; تعاني من أي مشاكل قلبية أخرى.</p><p dir="RTL">&bull; تعاني من مشاكل في الكبد.</p><p dir="RTL">&bull; تعاني من مشاكل في الكلى أو إذا كنت تخضع لغسيل الكلى،</p><p dir="RTL">&bull; تعاني من زيادة غير طبيعية في مستوى هرمون يسمى ألدوستيرون في الدم (فرط الألدوستيرونية الأولي) ،</p><p dir="RTL">&bull; تعاني من داء وعائي كولاجيني (وهو عبارة عن مرض في النسيج الضامّ) ، مثل الذئبة الحمامية الجهازية أو التصلّب الجلدي،</p><p dir="RTL">&bull;مصاب بداء السكري،</p><p dir="RTL">&nbsp;&bull;تتبع نظامًا غذائيًا مقيدًا للملح أو تستخدم بدائل الملح التي تحتوي على البوتاسيوم،</p><p dir="RTL">&nbsp;&bull;ستخضع للتخدير و / أو جراحة كبرى،</p><p dir="RTL">&nbsp;&bull;ستخضع للسحب الآلي للبروتين الشحمي المنخفض الكثافة (LDL) (أي عمليّة آليّة لسحب الكوليسترول من الدم) ،</p><p dir="RTL">&nbsp;&bull;ستخضع لعلاج لمكافحة التحسّس لتخفيف تأثير لدغات النحل والدبابير،</p><p dir="RTL">&nbsp;&bull;عانيت مؤخرًا من الإسهال أو القيء أو الجفاف.</p><p dir="RTL">&nbsp;&bull;أخبرك طبيبك أن لديك حساسية تجاه بعض السكريات.</p><p dir="RTL">&nbsp;&bull; تتناول أيًا من الأدوية التالية المستخدمة في علاج ارتفاع ضغط الدم:</p><p dir="RTL">- &nbsp;&quot;حاصرات مستقبلات الأنجيوتنسين &Iota;&Iota;&quot; (تُعرف أيضًا باسم سارتانز - على سبيل المثال فالسارتان، وتيلميسارتان، وإربيسارتان)، خاصة إذا كنت تعاني من مشاكل في الكلى مرتبطة بمرض السكري,</p><p dir="RTL">- اليسكيرين,</p><p dir="RTL">قد يفحص طبيبك وظائف الكلى وضغط الدم وكمية الشوارد الكهربائية (مثل البوتاسيوم) في دمك على فترات منتظمة.</p><p dir="RTL">انظر أيضًا المعلومات الواردة تحت عنوان &quot;لا تتناول سينوريل&quot;</p><p dir="RTL">&nbsp;&bull;تنتمي إلى العرق الأسود لأنك قد تكون أكثر عرضة للإصابة بالوذمة الوعائية وقد يكون هذا الدواء أقل فعالية في خفض ضغط الدم مقارنة بالمرضى من غير العرق الأسود.</p><p dir="RTL">&nbsp;&bull;إذا كنت تتناول أي من الأدوية التالية، فإن خطر الإصابة بالوذمة الوعائية يزداد:</p><p dir="RTL">- راسيكادوتريل (يستخدم لعلاج الإسهال)،</p><p dir="RTL">- سيروليموس، إيفيروليموس، تمسيروليموس والأدوية الأخري التي تنتمي إلى مجموعة الأدوية التي تدعى مثبطات الهدف الميكانيكي لرابامايسين m-TOR inhibitors &nbsp;(التي تستخدم لتجنب رفض الأعضاء المزروعة و تستخدم للسرطان)،</p><p dir="RTL">- ساكوبتريل (متوفر على شكل تركيبة ثابتة الجرعة مع فالسارتان)، الذي يستعمل لعلاج فشل القلب طويل الأمد.</p><p dir="RTL">- ليناجلبتن وساكساجلبتن وسيتاجلبتن وفيلداجلبتن وأدوية أخرى تنتمي إلى مجموعة تسمى الجلبتنز (تستخدم لعلاج مرض السكري).</p><p dir="RTL"><u>الوذمة الوعائية</u></p><p dir="RTL">تم الإبلاغ عن الوذمة الوعائية (رد فعل تحسسي شديد مع تورم في الوجه والشفتين واللسان أو الحلق مع صعوبة في البلع أو التنفس) في المرضى الذين يعالجون بمثبطات الإنزيم المحول للأنجيوتنسين، ومن ضمنها سينوريل. قد يحدث هذا في أي وقت أثناء العلاج. إذا ظهرت لديك مثل هذه الأعراض، يجب عليك التوقف عن تناول سينوريل ومراجعة الطبيب على الفور. انظر أيضًا القسم 4.</p><p dir="RTL">يجب عليكِ إخبار طبيبك إذا كنتِ حامل <u>(أو إن كنتِ تتوقعين الحمل)</u>. لا ينصح باستخدام سينوريل في بداية الحمل، ويجب عدم تناوله بعد الشهر الثالث للحمل، لأنه قد يسبب ضررًا خطيرًا لطفلك إذا تم استخدامه في تلك المرحلة (انظري &ldquo;الحمل والرضاعة&rdquo;).</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا ينصح باستخدام بيريندوبريل للأطفال والمراهقين حتى عمر 18 سنة.<strong>&nbsp;</strong></p><p dir="RTL"><strong>سينوريل والأدوية الأخرى </strong></p><p dir="RTL">يرجى إخبار طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">يمكن أن يتأثر العلاج بـ سينوريل بالأدوية الأخرى. قد يحتاج طبيبك إلى تغيير جرعتك و / أو اتخاذ احتياطات أخرى. وتشمل هذه:</p><p dir="RTL">&nbsp;&bull;الأدوية الأخرى لارتفاع ضغط الدم، بما في ذلك حاصرات مستقبلات الأنجيوتنسين &Iota;&Iota;، أليسكيرين (انظر أيضًا المعلومات الواردة تحت العناوين (&quot;لا تتناول سينوريل&quot; و &quot;المحاذير والاحتياطات&quot;) أو مدرات البول (أي الأدوية التي ترفع مقدار البول الناتج عن الكليتين)</p><p dir="RTL">&nbsp;&bull;الأدوية التي تحافظ على البوتاسيوم (مثل تريامتيرين، أميلوريد) ، مكملات البوتاسيوم أو بدائل الملح المحتوية على البوتاسيوم، أدوية أخرى يمكنها رفع معدلات البوتاسيوم في جسمك (مثل الهيبارين وكوتريموكسازول الذي يعرف أيضا باسم تريميثوبريم/سلفاميثوكسازول، تستخدم للعدوى البكتيرية) ،</p><p dir="RTL">&nbsp;&bull;الأدوية الحافظة للبوتاسيوم المستخدمة في علاج فشل القلب: إيبليرينون وسبيرونولاكتون بجرعات تتراوح بين 12.5 ملجم إلى 50 ملجم في اليوم.</p><p dir="RTL">&nbsp;&bull;الليثيوم المُستعمل في علاج الذهان الهَوَسي أو الاكتئاب،</p><p dir="RTL">&nbsp;&bull;الأدوية المضادة للالتهاب غير الستيرويديّة (مثل الإيبوبروفين) التي تستعمل لمكافحة الألم أو الجرعات المرتفعة من حمض أسيتيل الساليسيليك، وهي مادة موجودة في العديد من الأدوية المستخدمة لتخفيف الألم وخفض الحمى، وكذلك لمنع تخثر الدم،</p><p dir="RTL">&nbsp;&bull;الأدوية المستخدمة في علاج مرض السكري (مثل الأنسولين أو الميتفورمين).</p><p dir="RTL">&nbsp;&bull;باكلوفين (يستخدم لعلاج تصلب العضلات في الاضطرابات مثل التصلب اللويحي) ،</p><p dir="RTL">&nbsp;&bull;الأدوية المستعملة في علاج الاضطرابات العقلية مثل الاكتئاب أو القلق أو الفصام إلخ (منها مضادات الاكتئاب ثلاثيّة الحلقات ومضادات الذهان) ،</p><p dir="RTL">&nbsp;&bull;مثبطات المناعة (الأدوية التي تقلل آلية المناعة في الجسم) المستعملة في علاج أمراض المناعة الذاتيّة أو بعد عمليّة زراعة الأعضاء (منها سيكلوسبورين، تاكروليموس) ،</p><p dir="RTL">&nbsp;&bull;تريميثوبريم (لعلاج حالات العدوى).</p><p dir="RTL">&nbsp;&bull;إسترامُستين (المستخدم في علاج السرطان) ،</p><p dir="RTL">&nbsp;&bull;الأدوية التي تستخدم في الغالب لعلاج الإسهال (راسيكادوتريل) أو تجنب رفض الأعضاء المزروعة (سيروليموس، إيفيرليموس، تيمسيروليموس وعقاقير أخرى تنتمي إلى فئة ما يسمى مثبطاتmTor) انظر &quot;المحاذير والاحتياطات&quot;،</p><p dir="RTL">&nbsp;&bull;ساكوبيتريل / فالسارتان (يستخدم لعلاج فشل القلب طويل الأمد). انظر قسم &quot;لا تتناول سينوريل&quot; و &quot;المحاذير والاحتياطات&quot;</p><p dir="RTL">&nbsp;&bull;آلوبورينول (لعلاج النقرس).</p><p dir="RTL">&nbsp;&bull;بروكايين آميد (لعلاج عدم انتظام ضربات القلب).</p><p dir="RTL">&nbsp;&bull; الموسّعات الوعائيّة بما في ذلك النترات (المنتجات التي تجعل الأوعية الدموية تتسع) ،</p><p dir="RTL">&nbsp;&bull;الأدوية المستخدمة لعلاج انخفاض ضغط الدم أو الصدمة أو في علاج الربو (مثل إيفيدرين أو نورادرينالين أو أدرينالين) ،</p><p dir="RTL">&nbsp;&bull;أملاح الذهب، وخاصة التي تعطى داخل الوريد (والتي تستعمل لعلاج أعراض التهاب المفاصل الروماتويدي).</p><p dir="RTL"><strong>سينوريل مع الطعام والشراب</strong></p><p dir="RTL">يفضل تناول سينوريل قبل وجبة الطعام.<strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعة، تعتقدين أنك حامل أو تخططين لإنجاب طفل، اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب أن تخبري طبيبك إذا كنتِ تعتقدين بأنك حامل (<u>أو أنك قد تصبحين حاملًا</u>). سينصحك طبيبك في الأحوال الطبيعية بالتوقف عن تناول سينوريل قبل حدوث الحمل أو بمجرد أن تعلمي بحدوثه. وسوف ينصحك بتناول دواء آخر بدلًا عن سينوريل. يوصى بعدم تناول سينوريل منذ بداية الحمل، ولا يجوز أخذه على الإطلاق بعد الشهر الثالث للحمل، فقد يؤدي هذا إلى إصابات خطيرة للطفل.</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">أخبري طبيبك إذا كنتِ مرضعة أو على وشك البدء في الرضاعة الطبيعية. لا يُنصح بأخذ سينوريل لدى المرأة المرضع. فإن كنت مصرّة على الإرضاع، بإمكان طبيبك أن يختار لك دواء آخر، وخاصة إن كان الطفل حديث الولادة أو خديجا (مولودا قبل الأوان).</p><p dir="RTL"><strong>تأثير سينوريل على القيادة واستخدام الآلات</strong></p><p dir="RTL">عادة لا يؤثر سينوريل على اليقظة ولكن قد يحدث دوار أو ضعف بسبب انخفاض ضغط الدم لدى بعض المرضى. إذا حدث لك هذا، فقد تتأثر قدرتك على القيادة أو تشغيل الآلات.</p><p dir="RTL"><strong>يحتوي سينوريل على سكر الحليب (لاكتوز)</strong></p><p dir="RTL">يحتوي سينوريل على سكر الحليب (لاكتوز). فإن سبق وأعلمك طبيبك أو مزوّد الرعاية الصحية بعدم تحمّلك لبعض أنواع السكريات، فعليك باستشارة طبيبك أو مزوّد الرعاية الصحية قبل أخذ هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">يجب ابتلاع القرص مع كأس من الماء، ويُستحسن أخذه يوميّاً في نفس التوقيت في الصباح قبل وجبة الإفطار. إن طبيبك هو الذي يحدّد مقدار الجرعة المناسبة لك.</p><p dir="RTL">الجرعات الموصى بها هي كما يلي:</p><p dir="RTL">ارتفاع ضغط الدم: جرعة البدء والمداومة المعتادة 5 ملجم مرة واحدة يومياً. وإن تطلّب الأمر، يمكن رفع هذه الجرعة، بعد شهر من العلاج إلى 10 ملجم مرة في اليوم. 10 ملجم في اليوم هي الجرعة القصوى الموصى بها لعلاج ارتفاع ضغط الدم. إذا كان عمرك 65 عامًا أو أكثر، فإن جرعة البدء المعتادة هي 2.5 ملجم مرة في اليوم. بعد شهر يمكن زيادتها إلى 5 ملجم مرة في اليوم ثم إذا لزم الأمر إلى 10 ملجم مرة واحدة يومياً.</p><p dir="RTL">فشل القلب: جرعة البدء المعتادة 2.5 ملجم مرة في اليوم. بعد أسبوعين، يمكن زيادتها إلى 5 ملجم مرة في اليوم، وهي الجرعة القصوى الموصى بها لفشل القلب.</p><p dir="RTL">مرض الشريان التاجي الثابت: الجرعة المعتادة في بداية العلاج عبارة عن 5 ملجم مرة في اليوم، يمكن رفعها، بعد أسبوعين من العلاج، إلى 10ملجم مرة في اليوم وهي الجرعة القصوى الموصى بها في هذه الحالة. إذا كان عمرك 65 عامًا أو أكثر، تكون الجرعة المعتادة في بداية العلاج عبارة عن 2.5 ملجم مرة في اليوم، يمكن رفعها، بعد أسبوع من العلاج، إلى 5 ملجم، ثم الأسبوع التالي إلى 10 ملجم مرة في اليوم.</p><p dir="RTL"><strong>الاستخدم للأطفال والمراهقين</strong></p><p dir="RTL">لا ينصح باستخدامه للأطفال والمراهقين.</p><p dir="RTL"><strong>إذا تناولت سينوريل أكثر من اللازم</strong></p><p dir="RTL">إذا تناولت الكثير من الأقراص، فاتصل بأقرب قسم للحوادث والطوارئ أو أخبر طبيبك على الفور. التأثير الأكثر احتمالًا في حالة الجرعة الزائدة هو انخفاض ضغط الدم الذي يمكن أن يجعلك تشعر بالدوار والإغماء. إذا حدث هذا، يمكن أن يساعدك الاستلقاء مع رفع ساقيك للأعلى.<strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت تناول سينوريل &nbsp;</strong></p><p dir="RTL">من المهم تناول دواءك كل يوم لأن العلاج المنتظم يعمل بشكل أفضل. ومع ذلك، إذا نسيت تناول جرعة من سينوريل، فتناول الجرعة التالية في الوقت المعتاد. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>إذا توقفت عن تناول سينوريل &nbsp;</strong></p><p dir="RTL">بما أن العلاج بـ سينوريل عادة ما يكون مدى الحياة، يجب أن تتحدث مع طبيبك قبل إيقافه.</p><p dir="RTL">إذا كانت لديك أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">توقف عن تناول المستحضر الطبي واستشر الطبيب فورًا، إذا واجهت أيًا من الأعراض الجانبية التالية التي يمكن أن تكون خطيرة:</p><p dir="RTL">&nbsp;&bull;تورم الوجه والشفتين أو الفم أو اللسان أو الحلق وصعوبة التنفس (الوذمة الوعائية) (انظر القسم 2 &quot; المحاذير والاحتياطات&quot;) (غير شائعة - قد تظهر لدى شخص من كل 100 شخص).</p><p dir="RTL">&nbsp;&bull;الدوخة الشديدة أو الإغماء بسبب انخفاض ضغط الدم (قد يؤثر على شخص من كل 10 أشخاص).</p><p dir="RTL">&nbsp;&bull;ضربات قلب سريعة أو غير منتظمة بشكل غير عادي، ألم في الصدر (ذبحة صدرية) أو سكتة قلبية (نادر جدًا - قد تظهر لدى شخص من كل 10000 شخص).</p><p dir="RTL">&nbsp;&bull;ضعف في الذراعين أو الساقين، أو صعوبة في الكلام والتي يمكن أن تكون علامة على احتمالية حدوث سكتة دماغية (نادرة جدًا - قد تظهر لدى شخص من كل 10000 شخص).</p><p dir="RTL">&nbsp;&bull; صفير مفاجئ في الصدر، ألم في الصدر، ضيق في التنفس، أو صعوبة في التنفس (تشنج قصبي) (غير شائعة - قد تظهر لدى شخص من كل 100 شخص).</p><p dir="RTL">&nbsp;&bull;التهاب البنكرياس الذي قد يسبب ألمًا شديدًا في البطن والظهر مصحوبًا بالشعور بتوعك شديد (نادرة جدًا - قد تظهر لدى شخص من كل 10000 شخص).</p><p dir="RTL">&nbsp;&bull;اصفرار لون الجلد أو العينين (يرقان) الذي يمكن أن يكون علامة على التهاب الكبد (نادرة جدا - قد تظهر لدى شخص من كل 10000 شخص).</p><p dir="RTL">&nbsp;&bull;طفح جلدي يبدأ غالبًا ببقع حمراء مثيرة للحكة على وجهك أو ذراعيك أو ساقيك (حمامي عديدة الأشكال) (نادرة جدًا - قد تظهر لدى شخص من كل 10000 شخص).</p><p dir="RTL"><strong>أخبر طبيبك إذا لاحظت أيًا من الآثار الجانبية التالية</strong><strong>:</strong></p><p dir="RTL"><strong>شائعة (قد تظهر لدى شخص من كل 10 أشخاص)</strong><strong>:</strong></p><p dir="RTL">&nbsp;&bull;الصداع،</p><p dir="RTL">&nbsp;&bull;الدوخة،</p><p dir="RTL">&nbsp;&bull;الدوار،</p><p dir="RTL">&nbsp;&bull;الإحساس بوخز دبابيس وإبر،</p><p dir="RTL">&nbsp;&bull;اضطرابات الرؤية،</p><p dir="RTL">&nbsp;&bull;طنين (الإحساس بالضجيج في الأذن) ،</p><p dir="RTL">&nbsp;&bull;كحة،</p><p dir="RTL">&nbsp;&bull;ضيق التنفس.</p><p dir="RTL">&nbsp;&bull;اضطرابات الجهاز الهضمي (الغثيان والقيء وآلام البطن واضطرابات في التذوّق وعسر الهضم والإسهال والإمساك).</p><p dir="RTL">&nbsp;&bull;الحساسية (مثل الطفح الجلدي والحكة).</p><p dir="RTL">&nbsp;&bull;تشنجات العضلات،</p><p dir="RTL">&nbsp;&bull;الشعور بالتعب.</p><p dir="RTL"><strong>غير شائعة (قد تظهر لدى شخص من كل 100 شخص)</strong><strong>:</strong></p><p dir="RTL">&nbsp;&bull;كآبة،</p><p dir="RTL">&nbsp;&bull;تقلب المزاج،</p><p dir="RTL">&nbsp;&bull;اضطرابات النوم،</p><p dir="RTL">&nbsp;&bull;جفاف الفم،</p><p dir="RTL">&nbsp;&bull;حكة شديدة أو طفح جلدي شديد،</p><p dir="RTL">&nbsp;&bull; تشكل تجمعات نفاطية على الجلد،</p><p dir="RTL">&nbsp;&bull;مشاكل في الكلى،</p><p dir="RTL">&nbsp;&bull;ضعف جنسى،</p><p dir="RTL">&nbsp;&bull;التعرق،</p><p dir="RTL">&nbsp;&bull; زيادة عدد اليوزينيات (نوع من كريات الدم البيضاء) ،</p><p dir="RTL">&nbsp;&bull;النعاس،</p><p dir="RTL">&nbsp;&bull;الإغماء،</p><p dir="RTL">&nbsp;&bull;الخفقان،</p><p dir="RTL">&nbsp;&bull;تسارع نبضات القلب،</p><p dir="RTL">&nbsp;&bull;التهاب الأوعية الدموية،</p><p dir="RTL">&nbsp;&bull;تفاعلات تحسسية ضوئية (زيادة تحسس الجلد تجاه الشمس) ،</p><p dir="RTL">&nbsp;&bull;ألم مفصلي،</p><p dir="RTL">&nbsp;&bull;ألم عضلي،</p><p dir="RTL">&nbsp;&bull;ألم في الصدر،</p><p dir="RTL">&nbsp;&bull;توعّك،</p><p dir="RTL">&nbsp;&bull;وذمة محيطية،</p><p dir="RTL">&nbsp;&bull; ارتفاع الحرارة،</p><p dir="RTL">&nbsp;&bull;سقوط،</p><p dir="RTL">&nbsp;&bull;ارتفاع معدّل البوتاسيوم في الدم القابل للتراجع بعد إيقاف الدواء، انخفاض معدّل الصوديوم، انخفاض شديد في معدّل سكر الدم لدى المرضى المصابين بالسكري، ارتفاع معدّل اليوريا في الدم، وارتفاع معدّل الكرياتينين في الدم.</p><p dir="RTL"><strong>نادرة (قد تظهر لدى شخص من كل 1000 شخص)</strong><strong>:</strong></p><p dir="RTL">&nbsp;&bull;فشل كلوي حاد،</p><p dir="RTL">&nbsp;&bull;بول داكن اللون، الشعور بالغثيان أو الإصابة به، تقلصات العضلات، الارتباك والنوبات. هذه الأعراض قد تكون ناجمة عن إفراز غير مناسب من الهرمون المضاد للإدرار (متلازمة الإفراز غير المناسب من الهرمون المضاد للإدرار)</p><p dir="RTL">&nbsp;&bull; نقص أو انعدام إنتاج البول.</p><p dir="RTL">&nbsp;&bull;احمرار الوجه،</p><p dir="RTL">&nbsp;&bull;تفاقم الصدفية،</p><p dir="RTL">&nbsp;&bull; تغير في المعايير المخبرية: زيادة مستوى إنزيمات الكبد، ارتفاع مستوى البيليروبين في الدم.</p><p dir="RTL"><strong>نادرة جدًا (قد تظهر لدى شخص من كل 10000 شخص)</strong><strong>:</strong></p><p dir="RTL">&nbsp;&bull;ارتباك،</p><p dir="RTL">&nbsp;&bull;الالتهاب الرئوي اليوزيني (نوع نادر من الالتهاب الرئوي) ،</p><p dir="RTL">&nbsp;&bull; زكام (انسداد أو سيلان الأنف) ،</p><p dir="RTL">&nbsp;&bull;تغيرات في قيم الدم مثل نقص أعداد الكريات البيضاء والحمراء، انخفاض الهيموغلوبين، تناقص عدد الصفيحات الدموية.</p><p dir="RTL">إذا كانت لديك هذه الأعراض، فاتصل بطبيبك في أقرب وقت ممكن.</p><p dir="RTL">التردد غير معروف (لا يمكن تقديره من البيانات المتاحة):</p><p dir="RTL">&bull; تغير اللون، وخدر وألم في أصابع اليدين أو القدمين (ظاهرة رينو).</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إن كان لديك أعراض جانبية أو لاحظت أعراض غير مذكورة في هذه النشرة، فضلاً ابلغ الطبيب أو الصيدلي.</p><p dir="RTL"><strong>الإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>الأعراض</strong><strong> </strong><strong>الجانبية</strong><strong>:</strong></p><p dir="RTL"><strong>&bull;</strong><strong>المملكة</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>السعودية:</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">مركز الاتصال الموحد :&nbsp;&nbsp; &nbsp;19999</p><p dir="RTL">البريد الإلكتروني:&nbsp;&nbsp; &nbsp;npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&bull;</strong><strong>دول</strong><strong> </strong><strong>الخليج</strong><strong> </strong><strong>الأخرى</strong><strong>:</strong></p><p dir="RTL">الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; احفظ هذا الدواء بعيدًا عن متناول الأطفال.</p><p dir="RTL">&bull; لا تستخدمها بعد تاريخ انتهاء الصلاحية المطبوع على العبوة بعد &quot;EXP:&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&bull; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&bull; يجب عدم التخلص من الأدوية في مياه الصرف أو مع مخلفات المنزل. أسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجتها. لأن هذه الإجراءات ستساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المادة الفعالة هي</strong> بيريندوبريل ارجنين</p><p dir="RTL">&nbsp;<u>سينوريل 5 ملجم:</u> كل قرص يحتوي على 5 ملجم من بيريندوبريل ارجنين,</p><p dir="RTL"><u>سينوريل 10 ملجم:</u> كل قرص يحتوي على 10 ملجم من بيريندوبريل ارجنين,</p><p dir="RTL"><strong>المكونات الأخرى هي</strong> رذاذ اللاكتوز المجفف, جلايكولات نشا الصوديوم, مالتوديكسترين 19, ثاني أكسيد السيليكون الغروي, ستيرات المغنيسيوم, أوبادري II ازرق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>سينوريل</u></strong><u> 5 ملجم</u><strong> </strong>هي أقراص زرقاء اللون، مستطيلة الشكل ومغلفة غشائياً، منقوش عليها &ldquo;F7&rdquo; على جانب واحد وخط للكسر على الجانب الاخر، يمكن تقسيم القرص لنصفين متساويين.</p><p dir="RTL"><strong><u>سينوريل </u></strong><u>10 ملجم</u><strong> </strong>هي أقراص زرقاء اللون، مستديرة الشكل ومغلفة غشائياً، منقوش عليها &quot;F6&quot; على جانب واحد ولا يوجد نقش على الجانب الاخر.</p><p dir="RTL">تتوفر <strong>أقراص سينوريل المغلفة غشائيًا </strong>في شريط يحتوي على 10 أقراص وتحتوي كل علبة على ثلاث أشرطة (30 قرص).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة مصنع الرأي للصناعات الدوائية (ذ.م.م.)</p><p dir="RTL">الوادي، مبنى رقم 2684 ، الرقم الإضافي 6236 ، وحدة رقم 1</p><p dir="RTL">جدة 22518 شارع المعتصم بالله الفاطمي.</p><p dir="RTL">صندوق بريد: 9224 جدة - ٢١٤١٣ المملكة العربية السعودية</p><p>تلفون:&nbsp; &nbsp; 2888949&nbsp;&nbsp;12&nbsp;&nbsp; 966+</p><p dir="RTL">ايميل:&nbsp; Info@alraipharma.com&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم اعتماد هذه النشرة في10/2023 ، نسخة رقم 0 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cenoril 5 mg film-coated tablets
Cenoril 10 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Perindopril arginine.
5 mg
One film-coated tablet contains 5 mg perindopril arginine.
Excipient with known effect: 73 mg lactose.
10 mg
One film-coated tablet contains 10 mg perindopril arginine.
Excipient with known effect: 146 mg lactose.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
5 mg
Blue, oblong shaped film coated tablets embossed with “F7” on one side and break line on the other side. The tablet can be divided into equal halves.
10 mg
Blue, round shaped film-coated tablets embossed with “F6” on one side and plain on other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypertension</u>:</p><p>Treatment of hypertension.</p><p><u>Heart failure:</u></p><p>Treatment of symptomatic heart failure.</p><p><u>Stable coronary artery disease:</u></p><p>Reduction of risk of cardiac events in patients with a history of myocardial infarction and/or revascularisation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dose should be individualised according to the patient profile (see section 4.4) and blood pressure response.</p><p><u>Hypertension:</u></p><p>Cenoril may be used in monotherapy or in combination with other classes of antihypertensive therapy (see sections 4.3, 4.4, 4.5 and 5.1)</p><p>The recommended starting dose is 5 mg given once daily in the morning.</p><p>Patients with a strongly activated renin-angiotensin-aldosterone system (in particular, renovascular hypertension, salt and/or volume depletion, cardiac decompensation or severe hypertension) may experience an excessive drop in blood pressure following the initial dose. A starting dose of 2.5 mg is recommended in such patients and the initiation of treatment should take place under medical supervision.</p><p>The dose may be increased to 10 mg once daily after one month of treatment.</p><p>Symptomatic hypotension may occur following initiation of therapy with Cenoril; this is more likely in patients who are being treated concurrently with diuretics. Caution is therefore recommended since these patients may be volume and/or salt depleted.</p><p>If possible, the diuretic should be discontinued 2 to 3 days before beginning therapy with Cenoril (see section 4.4).</p><p>In hypertensive patients in whom the diuretic cannot be discontinued, therapy with Cenoril should be initiated with a 2.5 mg dose. Renal function and serum potassium should be monitored. The subsequent dosage of Cenoril should be adjusted according to blood pressure response. If required, diuretic therapy may be resumed.</p><p>In elderly patients, treatment should be initiated at a dose of 2.5 mg which may be progressively increased to 5 mg after one month then to 10 mg if necessary depending on renal function (see table below).</p><p><u>Symptomatic heart failure:</u></p><p>It is recommended that Cenoril, generally associated with a non-potassium-sparing diuretic and/or digoxin and/or a beta-blocker, be introduced under close medical supervision with a recommended starting dose of 2.5 mg taken in the morning. This dose may be increased after 2 weeks to 5 mg once daily if tolerated. The dose adjustment should be based on the clinical response of the individual patient.</p><p>In severe heart failure and in other patients considered to be at high risk (patients with impaired renal function and a tendency to have electrolyte disturbances, patients receiving simultaneous treatment with diuretics and/or treatment with vasodilating agents), treatment should be initiated under careful supervision (see section 4.4).</p><p>Patients at high risk of symptomatic hypotension e.g. patients with salt depletion with or without hyponatraemia, patients with hypovolaemia or patients who have been receiving vigorous diuretic therapy should have these conditions corrected, if possible, prior to therapy with Cenoril. Blood pressure, renal function and serum potassium should be monitored closely, both before and during treatment with Cenoril (see section 4.4).</p><p><u>Stable coronary artery disease:</u></p><p>Cenoril should be introduced at a dose of 5 mg once daily for two weeks, then increased to 10 mg once daily, depending on renal function and provided that the 5 mg dose is well tolerated.</p><p>Elderly patients should receive 2.5 mg once daily for one week, then 5 mg once daily the next week, before increasing the dose up to 10 mg once daily depending on renal function (see Table 1 &ldquo;Dosage adjustment in renal impairment&rdquo;).The dose should be increased only if the previous lower dose is well tolerated.</p><p><strong>Special population:</strong></p><p><u>Patients with renal impairment:</u></p><p>Dosage in patients with renal impairment should be based on creatinine clearance as outlined in table 1 below:</p><p>Table 1: dosage adjustment in renal impairment</p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p>Creatinine clearance (ml/min)</p></td><td style="vertical-align:top"><p>Recommended dose</p></td></tr><tr><td style="vertical-align:top"><p>ClCR &ge; 60</p></td><td style="vertical-align:top"><p>5 mg per day</p></td></tr><tr><td style="vertical-align:top"><p>30 &lt; ClCR &lt; 60</p></td><td style="vertical-align:top"><p>2.5 mg per day</p></td></tr><tr><td style="vertical-align:top"><p>15 &lt; ClCR &lt; 30</p></td><td style="vertical-align:top"><p>2.5 mg every other day</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Haemodialysed patients *</p></td></tr><tr><td style="vertical-align:top"><p>ClCR &lt; 15</p></td><td style="vertical-align:top"><p>2.5 mg on the day of dialysis</p></td></tr></tbody></table><p>* Dialysis clearance of perindoprilat is 70 ml/min.</p><p>For patients on haemodialysis, the dose should be taken after dialysis.</p><p><u>Patients with hepatic impairment:</u></p><p>No dosage adjustment is necessary in patients with hepatic impairment (see sections 4.4 and 5.2).</p><p><u>Paediatric population:</u></p><p>The safety and efficacy of perindopril in children and adolescents aged below 18 years have not been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</p><p>Therefore, use in children and adolescents is not recommended.</p><p><strong>Method of administration</strong></p><p>For oral use.</p><p>Cenoril is recommended to be taken once daily in the morning before a meal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance, to any of the excipients or to any other ACE inhibitor;
• History of angioedema associated with previous ACE inhibitor therapy (see section 4.4);
• Hereditary or idiopathic angioedema;
• Second and third trimesters of pregnancy (see sections 4.4 and 4.6);
• Concomitant use of Cenorilwith aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1);
• Concomitant use with sacubitril/valsartan therapy, Cenorilmust not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan (see sections 4.4 and 4.5);
• Extracorporeal treatments leading to contact of blood with negatively charged surfaces (see section 4.5);
• Significant bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney (see section 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Stable coronary artery disease:</u></p><p>If an episode of unstable angina pectoris (major or not) occurs during the first month of perindopril treatment, a careful appraisal of the benefit/risk should be performed before treatment continuation.</p><p><u>Hypotension:</u></p><p>ACE inhibitors may cause a fall in blood pressure. Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients and is more likely to occur in patients who have been volume-depleted e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea or vomiting, or who have severe renin-dependent hypertension (see sections 4.5 and 4.8). In patients with symptomatic heart failure, with or without associated renal insufficiency, symptomatic hypotension has been observed. This is most likely to occur in those patients with more severe degrees of heart failure, as reflected by the use of high doses of loop diuretics, hyponatraemia or functional renal impairment. In patients at increased risk of symptomatic hypotension, initiation of therapy and dose adjustment should be closely monitored (see sections 4.2 and 4.8). Similar considerations apply to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.</p><p>If hypotension occurs, the patient should be placed in the supine position and, if necessary, should receive an intravenous infusion of sodium chloride 9 mg/ml (0.9%) solution. A transient hypotensive response is not a contraindication to further doses, which can be given usually without difficulty once the blood pressure has increased after volume expansion.</p><p>In some patients with congestive heart failure who have normal or low blood pressure, additional lowering of systemic blood pressure may occur with Cenoril.</p><p>This effect is anticipated and is usually not a reason to discontinue treatment. If hypotension becomes symptomatic, areduction of dose or discontinuation of Cenoril may be necessary.</p><p>Aortic and mitral valve stenosis / hypertrophic cardiomyopathy:</p><p>As with other ACE inhibitors, Cenoril should be given with caution to patients with mitral valve stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or hypertrophic cardiomyopathy.</p><p><u>Renal impairment:</u></p><p>In cases of renal impairment (creatinine clearance &lt; 60 ml/min) the initial perindopril dosage should be adjusted according to the patient&#39;s creatinine clearance (see section 4.2) and then as a function of the patient&#39;s response to treatment. Routine monitoring of potassium and creatinine are part of normal medical practice for these patients (see section 4.8).</p><p>In patients with symptomatic heart failure, hypotension following the initiation of therapy with ACE inhibitors may lead to some further impairment in renal function. Acute renal failure, usually reversible, has been reported in this situation.</p><p>In some patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney, who have been treated with ACE inhibitors, increases in blood urea and serum creatinine, usually reversible upon discontinuation of therapy, have been seen. This is especially likely in patients with renal insufficiency. If renovascular hypertension is also present there is an increased risk of severe hypotension and renal insufficiency. In these patients, treatment should be started under close medical supervision with low doses and careful dose titration. Since treatment with diuretics may be acontributory factor to the above, they should be discontinued and renal function should be monitored during the first weeks of Cenoril therapy.</p><p>Some hypertensive patients with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when Cenoril has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of the diuretic and/or Cenoril may be required.</p><p><u>Haemodialysis patients:</u></p><p>Anaphylactoid reactions have been reported in patients dialysed with high flux membranes, and treated concomitantly with an ACE inhibitor. In these patients consideration should be given to using a different type of dialysis membrane or different class of antihypertensive agent.</p><p><u>Kidney transplantation:</u></p><p>There is no experience regarding the administration of Cenoril in patients with a recent kidney transplantation.</p><p><u>Renovascular hypertension:</u></p><p>There is an increased risk of hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with ACE inhibitors (see section 4.3). Treatment with diuretics may be a contributory factor. Loss of renal function may occur with only minor changes in serum creatinine even in patients with unilateral renal artery stenosis.</p><p><u>Hypersensitivity/Angioedema:</u></p><p>Angioedema of the face, extremities, lips, mucous membranes, tongue, glottis and/or larynx has been reported rarely inpatients treated with ACE inhibitors, including Cenoril (see section 4.8). This may occur at any time during therapy<strong><em>.</em></strong></p><p>In such cases, Cenoril should promptly be discontinued and appropriate monitoring should be initiated and continued until complete resolution of symptoms has occurred. In those instances where swelling was confined to the face and lips the condition generally resolved without treatment, although antihistamines have been useful in relieving symptoms.</p><p>Angioedema associated with laryngeal oedema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, emergency therapy should be administered promptly. This may include the administration of adrenaline and/or the maintenance of a patent airway. The patient should be under close medical supervision until complete and sustained resolution of symptoms has occurred.</p><p>Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see section 4.3).</p><p>Intestinal angioedema has been reported rarely in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior facial angioedema and C-1esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan, or ultrasound or at surgery and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain.</p><p>The combination of perindopril with sacubitril/valsartan is contraindicated due to the increased risk of angioedema (see section 4.3). Sacubitril/valsartan must not be initiated until 36 hours after taking the last dose of perindopril therapy. If treatment with sacubitril/valsartan is stopped, perindopril therapy must not be initiated until 36 hours after the last dose of sacubitril/valsartan (see sections 4.3 and 4.5). Concomitant use of ACE inhibitors with NEP inhibitors (e.g. racecadotril),mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and gliptins (e.g. linagliptin, saxagliptin, sitagliptin, vildagliptin)may lead to an increased risk of angioedema (e.g. swelling of the airways or tongue, with or without respiratory impairment) (see section 4.5). Caution should be used when starting racecadotril, mTOR inhibitors (e.g. sirolimus,everolimus, temsirolimus) and gliptins (e.g. linagliptin, saxagliptin, sitagliptin, vildagliptin) in a patient already taking an ACE inhibitor.</p><p><u>Anaphylactoid reactions during low-density lipoproteins (LDL) apheresis:</u></p><p>Rarely, patients receiving ACE inhibitors during low-density lipoprotein (LDL) apheresis with dextran sulfate have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.</p><p><u>Anaphylactic reactions during desensitisation:</u></p><p>Patients receiving ACE inhibitors during desensitisation treatment (e.g. hymenoptera venom) have experienced anaphylactoid reactions.</p><p>In the same patients, these reactions have been avoided when the ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge.</p><p><u>Hepatic failure:</u></p><p>Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up (see section 4.8).</p><p><u>Neutropenia/Agranulocytosis/Thrombocytopenia/Anaemia:</u></p><p>Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors. Inpatients with normal renal function and no other complicating factors, neutropenia occurs rarely.</p><p>Perindopril should be used with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing impaired renal function. Some of these patients developed serious infections, which in a few instances did not respond to intensive antibiotic therapy. If perindopril is used in such patients, periodic monitoring of white blood cell counts is advised and patients should be instructed to report any sign of infection (e.g. sore throat, fever).</p><p><u>Race:</u></p><p>ACE inhibitors cause a higher rate of angioedema in black patients than in non-black patients.</p><p>As with other ACE inhibitors, perindopril may be less effective in lowering blood pressure in black people than in non-blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.</p><p><u>Cough:</u></p><p>Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non-productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.</p><p><u>Surgery/Anaesthesia:</u></p><p>In patients undergoing major surgery or during anaesthesia with agents that produce hypotension, Cenoril may block angiotensin II formation secondary to compensatory renin release. The treatment should be discontinued one day prior to the surgery. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.</p><p><u>Hyperkalaemia:</u></p><p>Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including perindopril,ACE inhibitors can cause hyperkalaemia because they inhibit the release of aldosterone. The effect is usually not significant in patients with normal renal function. Risk factors for the development of hyperkalaemia include those with renal insufficiency, worsening of renal function, age (&gt; 70 years), diabetes mellitus, intercurrent events, in particular dehydration, acute cardiac decompensation, metabolic acidosis and concomitant use of potassium-sparing diuretics (e.g.spironolactone, eplerenone, triamterene, or amiloride), potassium supplements or potassium-containing salt substitutes;or those patients taking other drugs associated with increases in serum potassium (e.g. heparin, co-trimoxazole alsoknown as trimethoprim/sulfamethoxazole) and especially aldosterone antagonists or angiotensin-receptor blockers.</p><p>The use of potassium supplements, potassium-sparing diuretics, or potassium-containing salt substitutes particularly in patients with impaired renal function may lead to a significant increase in serum potassium. Hyperkalaemia can cause serious, sometimes fatal arrhythmias. Potassium-sparing diuretics and angiotensin-receptor blockers should be used with caution in patients receiving ACE inhibitors, and serum potassium and renal function should be monitored. If concomitant use of the above-mentioned agents is deemed appropriate, they<u> </u>should be used with caution and with frequent monitoring of serum potassium (see section 4.5).</p><p><u>Diabetic patients:</u></p><p>In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should be closely monitored during the first month of treatment with an ACE inhibitor (see section 4.5).</p><p><u>Lithium:</u></p><p>The combination of lithium and perindopril is generally not recommended (see section 4.5).</p><p><u>Potassium-sparing drugs, potassium supplements or potassium-containing salt substitutes:</u></p><p>The combination of perindopril and potassium-sparing drugs, potassium supplements or potassium-containing salt substitutes is generally not recommended (see section 4.5).</p><p><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS):</u></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><u>Primary aldosteronism:</u></p><p>Patients with primary hyperaldosteronism generally will not respond to anti-hypertensive drugs acting through inhibition of the renin-angiotensin system. Therefore, the use of this product is not recommended.</p><p><u>Pregnancy:</u></p><p>ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p><u>Excipients:</u></p><p>Due to the presence of lactose, patients with rare hereditary problems of galactose intolerance, glucose-galactose malabsorption, or total lactase deficiency should not take this medicinal product.</p><p><u>Level of sodium:</u></p><p>Cenoril contains less than 1 mmol sodium (23 mg) per tablet, i.e. essentially &#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p><strong><em><u>Drugs increasing the risk of angioedema</u></em></strong></p><p>Concomitant use of ACE inhibitors with sacubitril/valsartan is contraindicated as this increases the risk of angioedema (see section 4.3 and 4.4). Sacubitril/valsartan must not be started until 36 hours after taking the last dose of perindopril therapy. Perindopril therapy must not be started until 36 hours after the last dose of sacubitril/valsartan (see sections 4.3and 4.4).</p><p>Concomitant use of ACE inhibitors with racecadotril, mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) andgliptins (e.g. linagliptin, saxagliptin, sitagliptin, vildagliptin) may lead to an increased risk for angioedema (see section 4.4).</p><p><strong><em><u>Drugs inducing hyperkalaemia</u></em></strong></p><p>Although serum potassium usually remains within normal limits, hyperkalaemia may occur in some patients treated with Cenoril. Some drugs or therapeutic classes may increase the occurrence of hyperkalaemia: aliskiren,potassium salts, potassium-sparing diuretics (e.g. spironolactone, triamterene or amiloride), ACE inhibitors, angiotensin-II receptors antagonists, NSAIDs, heparins, immunosuppressant agents such as ciclosporin or tacrolimus, trimethoprimand cotrimoxazole (trimethoprim/sulfamethoxazole), as trimethoprim is known to act as a potassium-sparing diuretic likeamiloride. The combination of these drugs increases the risk of hyperkalaemia. Therefore, the combination of Cenoril with the above-mentioned drugs is not recommended. If concomitant use is indicated, they should be used with caution and with frequent monitoring of serum potassium.</p><p><strong><em>Concomitant use contra-indicated (see section 4.3):</em></strong></p><p><u>Aliskiren</u>:</p><p>In diabetic or impaired renal patients, risk of hyperkalaemia, worsening of renal function and cardiovascular morbidity and mortality increase<em>.</em></p><p><u>Extracorporeal treatments:</u></p><p>Extracorporeal treatments leading to contact of blood with negatively charged surfaces such as dialysis or haemofiltration with certain high-flux membranes (e.g. polyacrylonitrile membranes) and low density lipoprotein apheresis with dextran sulfate due to increased risk of severe anaphylactoid reactions (see section 4.3). If such treatment is required, consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.</p><p><strong><em><u>Concomitant use not recommended (see section 4.4):</u></em></strong></p><p><u>Aliskiren</u>:</p><p>In patients other than diabetic or impaired renal patients, risk of hyperkalaemia, worsening of renal function and cardiovascular morbidity and mortality increase.</p><p><u>Concomitant therapy with ACE inhibitor and angiotensin-receptor blocker:</u></p><p>It has been reported in the literature that in patients with established atherosclerotic disease, heart failure, or with diabetes with end organ damage, concomitant therapy with ACE inhibitor and angiotensin-receptor blocker is associated with a higher frequency of hypotension, syncope, hyperkalaemia, and worsening renal function (including acute renal failure) as compared to use of a single renin-angiotensin-aldosterone system agent. Dual blockade (e.g., by combining an ACE-inhibitor with an angiotensin II receptor antagonist) should be limited to individually defined cases with close monitoring of renal function, potassium levels, and blood pressure.</p><p><u>Estramustine</u>:</p><p>Risk of increased adverse effects such as angioneurotic oedema (angioedema).</p><p><u>Potassium-sparing diuretics (e.g. triamterene, amiloride...), potassium salts:</u></p><p>Hyperkalaemia (potentially lethal), especially in conjunction with renal impairment (additive hyperkalaemic effects).</p><p>The combination of perindopril with the above-mentioned drugs is not recommended (see section 4.4). If concomitant use is nonetheless indicated, they should be used with caution and with frequent monitoring of serum potassium. For use of spironolactone in heart failure, see below.</p><p><u>Lithium</u>:</p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. Use of perindopril with lithium is not recommended, but if the combination proves necessary, careful monitoring of serum lithium levels should be performed (see section 4.4).</p><p><strong><em><u>Concomitant use which requires special care:</u></em></strong></p><p><u>Antidiabetic agents (insulins, oral hypoglycaemic agents):</u></p><p>Epidemiological studies have suggested that concomitant administration of ACE inhibitors and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood-glucose lowering effect with risk of hypoglycaemia.</p><p>This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment.</p><p><u>Baclofen:</u></p><p>Increased antihypertensive effect. Monitor blood pressure and adapt antihypertensive dosage if necessary.</p><p><u>Non-potassium-sparing diuretics:</u></p><p>Patients on diuretics, and especially those who are volume and/or salt depleted, may experience excessive reduction in blood pressure after initiation of therapy with an ACE inhibitor. The possibility of hypotensive effects can be reduced by discontinuation of the diuretic, by increasing volume or salt intake prior to initiating therapy with low and progressive doses of perindopril.</p><p><em>In arterial hypertension, </em>when prior diuretic therapy can have caused salt/volume depletion, either the diuretic must be discontinued before initiating the ACE inhibitor, in which case a non-potassium-sparing diuretic can be thereafter reintroduced or the ACE inhibitor must be initiated with a low dosage and progressively increased.</p><p><em>In diuretic-treated congestive heart failure, </em>the ACE inhibitor should be initiated at a very low dosage, possibly after reducing the dosage of the associated non-potassium-sparing diuretic.</p><p>In all cases, renal function (creatinine levels) must be monitored during the first few weeks of ACE inhibitor therapy.</p><p><u>Potassium-sparing diuretics (eplerenone, spironolactone):</u></p><p>With eplerenone or spironolactone at doses between 12.5 mg to 50 mg by day and with low doses of ACE inhibitors:</p><p>In the treatment of class II-IV heart failure (NYHA) with an ejection fraction &lt; 40%, and previously treated with ACE inhibitors and loop diuretics, risk of hyperkalaemia, potentially lethal, especially in case of non-observance of the prescription recommendations on this combination.</p><p>Before initiating the combination, check the absence of hyperkalaemia and renal impairment.</p><p>A close monitoring of the kalaemia and creatininaemia is recommended in the first month of the treatment once a week at the beginning and, monthly thereafter.</p><p><u>Non-steroidal anti-inflammatory medicinal products (NSAIDs) including acetylsalicylic acid &ge; 3 g/day:</u></p><p>When ACE-inhibitors are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. Concomitant use of ACE-inhibitors and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter</p><p><strong><em><u>Concomitant use which requires some care:</u></em></strong></p><p><u>Antihypertensive agents and vasodilators:</u></p><p>Concomitant use of these agents may increase the hypotensive effects of perindopril. Concomitant use with nitroglycerin and other nitrates, or other vasodilators, may further reduce blood pressure.</p><p><u>Tricyclic antidepressants/Antipsychotics/Anaesthetics:</u></p><p>Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and antipsychotics with ACE inhibitors may result in further reduction of blood pressure (see section 4.4).</p><p><u>Sympathomimetics:</u></p><p>Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.</p><p><u>Gold</u>:</p><p>Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely inpatients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including perindopril.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:622px"><tbody><tr><td style="vertical-align:top; width:619px"><p>The use of ACE inhibitors is not recommended during the first trimester of pregnancy (see section 4.4). The use of ACE inhibitors is contra-indicated during the 2nd and 3rd trimester of pregnancy (see sections 4.3 and 4.4).</p></td></tr></tbody></table><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded.</p><p>Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3). Should exposure to ACE inhibitor have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (see also sections 4.3 and 4.4).</p><p><u>Lactation:</u></p><p>Because no information is available regarding the use of Cenoril during breast-feeding, Cenoril is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p><u>Fertilit</u>y<u>:</u></p><p>There was no effect on reproductive performance or fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cenoril has no direct influence on the ability to drive and use machines but individual reactions related to low blood pressure may occur in some patients, particularly at the start of treatment or in combination with another antihypertensive medication.</p><p>As a result the ability to drive or operate machinery may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Summary of the safety profile</u></p><p>The safety profile of perindopril is consistent with the safety profile of ACE inhibitors:</p><p>The most frequent adverse events reported in clinical trials and observed with perindopril are: dizziness, headache, paraesthesia, vertigo, visual disturbances, tinnitus, hypotension, cough, dyspnoea, abdominal pain, constipation, diarrhoea, dysgeusia, dyspepsia, nausea, vomiting, pruritus, rash, muscle cramps, and asthenia.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Tabulated list of adverse reactions</u></p><p>The following undesirable effects have been observed during <u>clinical trials and/or post-marketing use</u> with perindopril and ranked under the following frequency:</p><p>Very common (&ge;1/10); common (&ge;1/100, &lt;1/10); uncommon (&ge;1/1000, &lt;1/100); rare (&ge;1/10000, &lt;1/1000); very rare (&lt;1/10000); not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA</strong></p><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Undesirable Effects</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p><strong>Blood and the lymphatic System Disorders</strong></p></td><td style="vertical-align:top"><p>Eosinophilia</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Agranulocytosis or pancytopenia</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Haemoglobin decreased and haematocrit decreased</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Leucopenia/neutropenia</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Haemolytic anaemia in patients with a congenital deficiency of G-6PDH (see section 4.4)</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top"><p>Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td style="vertical-align:top"><p>Hypoglycaemia (see sections 4.4 and 4.5)</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkalaemia, reversible on discontinuation (see section 4.4)</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatraemia</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Mood disturbances</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Sleep disorder</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p><strong>Nervous System disorders</strong></p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Confusion</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye Disorders</strong></p></td><td style="vertical-align:top"><p>Visual disturbances</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Cardiac Disorders</strong></p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Angina pectoris (see section 4.4)</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmia</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial infarction, possibly secondary to excessive hypotension in high risk patients (see section 4.4)</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top"><p>Hypotension (and effects related to hypotension)</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vasculitis</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>Rare*</p></td></tr><tr><td style="vertical-align:top"><p>Stroke possibly secondary to excessive hypotension in high-risk patients (see section 4.4)</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Raynaud&#39;s phenomenon</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Bronchospasm</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Eosinophilic pneumonia</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="9" style="vertical-align:top"><p><strong>Gastro-intestinal Disorders</strong></p></td><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dysgeusia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary Disorders</strong></p></td><td style="vertical-align:top"><p>Hepatitis either cytolytic or cholestatic (see section 4.4)</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="9" style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria (see section 4.4)</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema of face, extremities, lips, mucousmembranes, tongue, glottis and/or larynx (see section 4.4)</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Photosensitivity reactions</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Pemphigoid</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Psoriasis aggravation</p></td><td style="vertical-align:top"><p>Rare*</p></td></tr><tr><td style="vertical-align:top"><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Erythema multiforme</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Musculoskeletal And Connective Tissue Disorders</strong></p></td><td style="vertical-align:top"><p>Muscle cramps</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Renal and Urinary Disorders</strong></p></td><td style="vertical-align:top"><p>Renal insufficiency</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Acute renal failure</p></td><td style="vertical-align:top"><p>Rare*</p></td></tr><tr><td style="vertical-align:top"><p>Anuria/Oliguria</p></td><td style="vertical-align:top"><p>Rare*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive System and Breast Disorders</strong></p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>General Disorders and Administration Site Condition</strong></p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Malaise</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Oedema peripheral</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Blood urea increased</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr><tr><td style="vertical-align:top"><p>Blood bilirubin increased</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Hepatic enzyme increased</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>Fall</p></td><td style="vertical-align:top"><p>Uncommon*</p></td></tr></tbody></table><p><em>* Frequency calculated from clinical trials for adverse events detected from spontaneous report</em></p><p><u>Clinical trials:</u></p><p>During the randomised period of the EUROPA study, only serious adverse events were collected. Few patients experienced serious adverse events: 16 (0.3%) of the 6122 perindopril patients and 12 (0.2%) of the 6107 placebo patients. In perindopril-treated patients, hypotension was observed in 6 patients, angioedema in 3 patients and sudden cardiac arrest in 1 patient. More patients withdrew for cough, hypotension or other intolerance on perindopril than on placebo, 6.0% (n=366) versus 2.1% (n=129) respectively.</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>Other GCC States:</strong></p><p>- Please contact the relevant competent authority</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Limited data are available for overdosage in humans. Symptoms associated with overdosage of ACE inhibitors may include hypotension, circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety, and cough.</p><p>The recommended treatment of overdosage is intravenous infusion of sodium chloride 9 mg/ml (0.9%) solution. If hypotension occurs, the patient should be placed in the shock position. If available, treatment with angiotensin II infusion and/or intravenous catecholamines may also be considered. Perindopril may be removed from the general circulation by haemodialysis (see section 4.4). Pacemaker therapy is indicated for therapy-resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations should be monitored continuously.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: ACE inhibitor, plain, ATC code: C09AA04</p><p><strong>Mechanism of action</strong></p><p>Perindopril is an inhibitor of the enzyme that converts angiotensin I into angiotensin II (Angiotensin Converting Enzyme ACE). The converting enzyme, or kinase, is an exopeptidase that allows conversion of angiotensin I into the vasoconstrictor angiotensin II as well as causing the degradation of the vasodilator bradykinin into an inactive heptapeptide. Inhibition of ACE results in a reduction of angiotensin II in the plasma, which leads to increased plasma renin activity (by inhibition of the negative feedback of renin release) and reduced secretion of aldosterone. Since ACE inactivates bradykinin, inhibition of ACE also results in an increased activity of circulating and local kallikrein-kinin systems (and thus also activation of the prostaglandin system).</p><p>It is possible that this mechanism contributes to the blood pressure-lowering action of ACE inhibitors and is partially responsible for certain of their side effects (e.g. cough).</p><p>Perindopril acts through its active metabolite, perindoprilat. The other metabolites show no inhibition of ACE activity <em>in vitro</em>.</p><p><strong>Clinical efficacy and safety</strong></p><p><u>Hypertension</u>:</p><p>Perindopril is active in all grades of hypertension: mild, moderate, severe; a reduction in systolic and diastolic blood pressures in both supine and standing positions is observed.</p><p>Perindopril reduces peripheral vascular resistance, leading to blood pressure reduction. As a consequence, peripheral blood flow increases, with no effect on heart rate.</p><p>Renal blood flow increases as a rule, while the glomerular filtration rate (GFR) is usually unchanged.</p><p>The antihypertensive activity is maximal between 4 and 6 hours after a single dose and is sustained for at least 24 hours: trough effects are about 87-100 % of peak effects.</p><p>The decrease in blood pressure occurs rapidly. In responding patients, normalisation is achieved within a month and persists without the occurrence of tachyphylaxis.</p><p>Discontinuation of treatment does not lead to a rebound effect.</p><p>Perindopril reduces left ventricular hypertrophy.</p><p>In man, perindopril has been confirmed to demonstrate vasodilatory properties. It improves large artery elasticity and decreases the media: lumen ratio of small arteries.</p><p>An adjunctive therapy with a thiazide diuretic produces an additive-type of synergy. The combination of an ACE inhibitor and a thiazide also decreases the risk of hypokalaemia induced by the diuretic treatment.</p><p><u>Heart failure:</u></p><p>Perindopril reduces cardiac work by a decrease in pre-load and after-load.</p><p>Studies in patients with heart failure have demonstrated:</p><p>- decreased left and right ventricular filling pressures,</p><p>- reduced total peripheral vascular resistance,</p><p>- increased cardiac output and improved cardiac index.</p><p>In comparative studies, the first administration of 2.5 mg of perindopril arginine to patients with mild to moderate heart failure was not associated with any significant reduction of blood pressure as compared to placebo.</p><p><u>Patients with stable coronary artery disease:</u></p><p>The EUROPA study was a multicentre, international, randomised, double-blind, placebo-controlled clinical trial lasting 4 years.</p><p>Twelve thousand two hundred and eighteen (12218) patients aged over 18 were randomised to 8 mg perindopril tert-butylamine (equivalent to 10 mg perindopril arginine) (n=6110) or placebo (n=6108).</p><p>The trial population had evidence of coronary artery disease with no evidence of clinical signs of heart failure. Overall,90% of the patients had a previous myocardial infarction and/or a previous coronary revascularisation. Most of the patients received the study medication on top of conventional therapy including platelet inhibitors, lipid lowering agents and beta-blockers.</p><p>The main efficacy criterion was the composite of cardiovascular mortality, non-fatal myocardial infarction and/or cardiac arrest with successful resuscitation. The treatment with 8 mg perindopril tert-butylamine (equivalent to 10 mg perindopril arginine) once daily resulted in a significant absolute reduction in the primary endpoint of 1.9% (relative risk reduction of20%, 95%CI [9.4; 28.6] &ndash; p&lt;0.001).</p><p>In patients with a history of myocardial infarction and/or revascularisation, an absolute reduction of 2.2% corresponding to a RRR of 22.4% (95%CI [12.0; 31.6] &ndash; p&lt;0.001) in the primary endpoint was observed by comparison to placebo.</p><p><u>Paediatric use:</u></p><p>The safety and efficacy of perindopril in children and adolescents aged below 18 years have not been established.</p><p>In an open, non-comparative clinical study in 62 hypertensive children aged from 2 to 15 years with a glomerular filtration rate &gt; 30 ml/min/1.73 m<sup>2</sup>, patients received perindopril with an average dose of 0.07 mg/kg. The dose was individualized according to the patient profile and blood pressure response up to a maximum dose of 0.135 mg/kg/day.</p><p>59 patients completed the period of three months, and 36 patients completed the extension period of the study, i.e. were followed at least 24 months (mean study duration: 44 months).</p><p>Systolic and diastolic blood pressure remained stable from the inclusion to the last assessment in patients previously treated by other antihypertensive treatments, and decreased in na&iuml;ve patients.</p><p>More than 75% of children had systolic and diastolic blood pressure below the 95<sup>th</sup> percentile at their last assessment.</p><p>The safety was consistent with the known safety profile of perindopril.</p><p><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS) clinical trial data:</u></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed.</p><p>Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensinII receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker inpatients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;<u>Absorption</u></p><p>After oral administration, the absorption of perindopril is rapid and the peak concentration is achieved within 1 hour. The plasma half-life of perindopril is equal to 1 hour.</p><p>Perindopril is a prodrug. Twenty seven percent of the administered perindopril dose reaches the bloodstream as the active metabolite perindoprilat. In addition to active perindoprilat, perindopril yields five metabolites, all inactive. Thepeak plasma concentration of perindoprilat is achieved within 3 to 4 hours.</p><p>As ingestion of food decreases conversion to perindoprilat, hence bioavailability, perindopril arginine should be administered orally in a single daily dose in the morning before a meal.</p><p>It has been demonstrated a linear relationship between the dose of perindopril and its plasma exposure.</p><p><u>Distribution</u></p><p>The volume of distribution is approximately 0.2 l/kg for unbound perindoprilat. Protein binding of perindoprilat to plasma proteins is 20%, principally to angiotensin converting enzyme, but is concentration-dependent.</p><p><u>Elimination</u></p><p>Perindoprilat is eliminated in the urine and the terminal half-life of the unbound fraction is approximately 17 hours, resulting in steady-state within 4 days.</p><p><u>Special population</u></p><p>Elimination of perindoprilat is decreased in the elderly, and also in patients with heart or renal failure. Dosage adjustmentin renal insufficiency is desirable depending on the degree of impairment (creatinine clearance).</p><p>Dialysis clearance of perindoprilat is equal to 70 ml/min.</p><p>&nbsp; Perindopril kinetics are modified in patients with cirrhosis: hepatic clearance of the parent molecule is reduced by half. However, the quantity of perindoprilat formed is not reduced and therefore no dosage adjustment is required (seesections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the chronic oral toxicity studies (rats and monkeys), the target organ is the kidney, with reversible damage.</p><p>No mutagenicity has been observed in <em>in vitro </em>or <em>in vivo </em>studies.</p><p>Reproduction toxicology studies (rats, mice, rabbits and monkeys) showed no sign of embryotoxicity or teratogenicity.However, angiotensin converting enzyme inhibitors, as a class, have been shown to induce adverse effects on late foetal development, resulting in foetal death and congenital effects in rodents and rabbits: renal lesions and an increase in peri-and postnatal mortality have been observed. Fertility was not impaired either in male or in female rats.</p><p>No carcinogenicity has been observed in long term studies in rats and mice.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:276px"><tbody><tr><td><p><strong>S. No.</strong></p></td><td><p><strong>Ingredients</strong></p></td></tr><tr><td><p>1.</p></td><td><p>Spray dried Lactose</p></td></tr><tr><td><p>2.</p></td><td><p>Sodium starch glycolate</p></td></tr><tr><td><p>3.</p></td><td><p>Maltodextrin 19</p></td></tr><tr><td><p>4.</p></td><td><p>Colloidal silicon dioxide</p></td></tr><tr><td><p>5.</p></td><td><p>Magnesium Stearate</p></td></tr><tr><td><p>6.</p></td><td><p>Opadry II (32K205007) Blue</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Store below 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5 mg: </strong>Cenoril 5 mg is available in blister packs containing 10 tablets and each box contains 3 blisters (30 Tablets).</p><p><strong>10 mg: </strong>Cenoril 10 mg is available in blister packs containing 10 tablets and each box contains 3 blisters (30 Tablets).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alrai Pharmaceutical Industries Co. (L.L.C.)
Al Wadi, Building No. 2684, Additional No. 6236 
Unit No. 1, Jeddah 22518 Almu'tasem Bellah Al Fatemy Street 
P.O.Box : 9224, Postal code 21413. Kingdom of Saudi Arabia 
Tel: +966 12 2888949 
E-mail: info@alraipharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>